S&P 500   4,581.61 (+0.66%)
DOW   35,664.58 (+0.49%)
QQQ   381.76 (+0.46%)
AAPL   151.45 (+1.75%)
MSFT   321.57 (-0.50%)
FB   309.54 (-0.86%)
GOOGL   2,908.27 (-0.55%)
TSLA   1,059.80 (+2.11%)
AMZN   3,389.41 (-0.09%)
NVDA   245.76 (+0.51%)
BABA   167.80 (-0.85%)
NIO   39.43 (+0.31%)
CGC   12.94 (+1.25%)
GE   103.43 (-0.40%)
AMD   120.75 (-1.25%)
MU   70.03 (+2.62%)
T   25.53 (+1.88%)
F   17.46 (+12.57%)
ACB   6.93 (+1.32%)
DIS   169.38 (-0.10%)
PFE   43.53 (+1.30%)
BA   206.90 (+0.14%)
AMC   35.34 (+1.67%)
S&P 500   4,581.61 (+0.66%)
DOW   35,664.58 (+0.49%)
QQQ   381.76 (+0.46%)
AAPL   151.45 (+1.75%)
MSFT   321.57 (-0.50%)
FB   309.54 (-0.86%)
GOOGL   2,908.27 (-0.55%)
TSLA   1,059.80 (+2.11%)
AMZN   3,389.41 (-0.09%)
NVDA   245.76 (+0.51%)
BABA   167.80 (-0.85%)
NIO   39.43 (+0.31%)
CGC   12.94 (+1.25%)
GE   103.43 (-0.40%)
AMD   120.75 (-1.25%)
MU   70.03 (+2.62%)
T   25.53 (+1.88%)
F   17.46 (+12.57%)
ACB   6.93 (+1.32%)
DIS   169.38 (-0.10%)
PFE   43.53 (+1.30%)
BA   206.90 (+0.14%)
AMC   35.34 (+1.67%)
S&P 500   4,581.61 (+0.66%)
DOW   35,664.58 (+0.49%)
QQQ   381.76 (+0.46%)
AAPL   151.45 (+1.75%)
MSFT   321.57 (-0.50%)
FB   309.54 (-0.86%)
GOOGL   2,908.27 (-0.55%)
TSLA   1,059.80 (+2.11%)
AMZN   3,389.41 (-0.09%)
NVDA   245.76 (+0.51%)
BABA   167.80 (-0.85%)
NIO   39.43 (+0.31%)
CGC   12.94 (+1.25%)
GE   103.43 (-0.40%)
AMD   120.75 (-1.25%)
MU   70.03 (+2.62%)
T   25.53 (+1.88%)
F   17.46 (+12.57%)
ACB   6.93 (+1.32%)
DIS   169.38 (-0.10%)
PFE   43.53 (+1.30%)
BA   206.90 (+0.14%)
AMC   35.34 (+1.67%)
S&P 500   4,581.61 (+0.66%)
DOW   35,664.58 (+0.49%)
QQQ   381.76 (+0.46%)
AAPL   151.45 (+1.75%)
MSFT   321.57 (-0.50%)
FB   309.54 (-0.86%)
GOOGL   2,908.27 (-0.55%)
TSLA   1,059.80 (+2.11%)
AMZN   3,389.41 (-0.09%)
NVDA   245.76 (+0.51%)
BABA   167.80 (-0.85%)
NIO   39.43 (+0.31%)
CGC   12.94 (+1.25%)
GE   103.43 (-0.40%)
AMD   120.75 (-1.25%)
MU   70.03 (+2.62%)
T   25.53 (+1.88%)
F   17.46 (+12.57%)
ACB   6.93 (+1.32%)
DIS   169.38 (-0.10%)
PFE   43.53 (+1.30%)
BA   206.90 (+0.14%)
AMC   35.34 (+1.67%)
NASDAQ:CYTO

Altamira Therapeutics News Headlines

$1.69
0.00 (0.00 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.66
$1.72
50-Day Range
$1.60
$3.11
52-Week Range
$0.78
$6.60
Volume
48,594 shs
Average Volume
2.25 million shs
Market Capitalization
$19.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.09

Media Mentions By Week



Altamira Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYTO
News Sentiment

0.50

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYTO Articles
This Week

3

1

CYTO Articles
Average Week

Get Altamira Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter.

Altamira Therapeutics (NASDAQ:CYTO) News Headlines Today

SourceHeadline
finance.yahoo.com logoAltamira Therapeutics Ltd. (CYTO)
finance.yahoo.com - October 26 at 10:31 AM
finance.yahoo.com logoAltamira Therapeutics and Wellesta Collaborate for Marketing and Distribution of Bentrio in Six Key Asian Markets
finance.yahoo.com - October 25 at 2:07 PM
MarketBeat logoAltamira Therapeutics Ltd (NASDAQ:CYTO) Sees Large Decrease in Short Interest
americanbankingnews.com - October 19 at 8:38 AM
finance.yahoo.com logoAltamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application
finance.yahoo.com - October 14 at 8:57 AM
finance.yahoo.com logoAltamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference
finance.yahoo.com - October 6 at 11:42 AM
MarketBeat logoAltamira Therapeutics Ltd (NASDAQ:CYTO) Short Interest Update
americanbankingnews.com - October 5 at 9:56 AM
finance.yahoo.com logoAltamira Therapeutics Provides Update on Bentrio Program
finance.yahoo.com - September 27 at 7:51 AM
finanznachrichten.de logoAltamira Therapeutics to Provide Business Update on Bentrio Program
finanznachrichten.de - September 24 at 12:01 AM
finance.yahoo.com logoAltamira Therapeutics to Provide Business Update on Bentrio(TM) Program
finance.yahoo.com - September 21 at 9:24 AM
finance.yahoo.com logoAltamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 9 at 12:18 PM
finance.yahoo.com logoAltamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results
finance.yahoo.com - September 8 at 10:37 AM
finance.yahoo.com logoAltamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)
finance.yahoo.com - August 6 at 1:45 PM
barrons.com logoAltamira Therapeutics Ltd.
barrons.com - August 5 at 7:18 PM
reuters.com logoCYTO.OQ - Altamira Therapeutics Ltd Profile | Reuters
reuters.com - August 5 at 9:18 AM
finance.yahoo.com logoAltamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray
finance.yahoo.com - August 3 at 9:21 AM
Get Altamira Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.